141047-47-4

Usage

General Description

1-Piperidinecarboxaldehyde, 4-(2-hydroxyethyl)- (9CI) is a chemical compound with the molecular formula C8H13NO2. It is a piperidine derivative with a hydroxyethyl substituent at the fourth position. 1-Piperidinecarboxaldehyde, 4-(2-hydroxyethyl)- (9CI) is commonly used in the synthesis of various pharmaceutical and organic compounds. It can act as a building block for the preparation of other complex molecules due to its functional group reactivity. Additionally, it is also used as a starting material for the synthesis of heterocyclic compounds and as a reagent in organic chemistry reactions. 1-Piperidinecarboxaldehyde, 4-(2-hydroxyethyl)- (9CI) is important for the development of new drugs and agrochemicals due to its versatile chemical properties and reactivity.

Upstream product

• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 107-31-3 Methyl formate 
• 64-18-6 formic acid 

Downstream Products

• 70724-70-8 4-(2-methoxyethyl)piperidine 
• 141047-63-4 4-(2-methoxyethyl)piperidine amide of L-phenyllactic acid 
• 141047-81-6 (S)-2-{(S)-1-Benzyl-2-[4-(2-methoxy-ethyl)-piperidin-1-yl]-2-oxo-ethoxy}-hexanoic acid 
• 141062-21-7 (S)-2-{(S)-1-Benzyl-2-[4-(2-methoxy-ethyl)-piperidin-1-yl]-2-oxo-ethoxy}-hexanoic acid ((1S,2R,3S)-1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexyl)-amide 
• 1156468-26-6 2-(1-formyl-4-piperidyl)ethyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Discovery of (2 S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl) sulfanyl]-9 H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor

Modulation of Hsp90 (heat shock protein 90) function has been recognized as an attractive approach for cancer treatment, since many cancer cells depend on Hsp90 to maintain cellular homeostasis. This has spurred the search for small-molecule Hsp90 inhibitors. Here we describe our lead optimization studies centered on the purine-based Hsp90 inhibitor 28a containing a piperidine moiety at the purine N9 position. In this study, key SAR was established for the piperidine N-substituent and for the congeners of the 1,3-benzodioxole at C8. These efforts led to the identification of orally bioavailable 28g that exhibits good in vitro profiles and a characteristic molecular biomarker signature of Hsp90 inhibition both in vitro and in vivo. Favorable pharmacokinetic properties along with significant antitumor effects in multiple human cancer xenograft models led to the selection of 28g (MPC-3100) as a clinical candidate.

Indium-catalyzed N -formylation of amines under solvent-free conditions

We have developed a simple, mild method for N-formylation of a wide variety of amines in the presence of indium metal as a catalyst under solvent-free conditions. This reaction is applicable to the chemoselective N-formylation of amino groups and -amino acid esters without epimerization. Georg Thieme Verlag Stuttgart.

Nonpeptide Renin Inhibitors Employing a Novel 3-Aza(or oxa)-2,4-dialkyl Glutaric Acid Moiety as a P2/P3 Amide Bond Replacement

A new series of renin inhibitors has been developed.The inhibitors feature a novel replacement for the P2/P3 dipeptide moiety normally associated with renin inhibitors.The dipeptide replacement was a (2S,4S)-3-aza(or oxa)-2,4-dialkylglutaric acid amide.Ex